Phase I, Double-Blind, Randomized, Single-Center, Five-Period Crossover Study to Assess the Effects of Single Oral Doses of 400 mg and 1000 mg of PA-824 and 400 mg of PA-824 Plus 400 mg of Moxifloxacin on QTc Interval Compared to Placebo, Using AVELOX(R) (Moxifloxacin) as a Positive Control, in Healthy Male and Female Volunteers Aged 18 to 45 Years
Phase of Trial: Phase I
Latest Information Update: 10 Dec 2014
At a glance
- Drugs Pretomanid (Primary) ; Moxifloxacin
- Indications Tuberculosis
- Focus Adverse reactions
- 14 Feb 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 27 Sep 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 05 Sep 2012 New trial record